Dmitri Lissin, MD

Chief Medical Officer
Scilex Holding Company
Palo Alto, California

Disclosure information not submitted.

Presentation(s):

• Decreased Healthcare Resource Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch : A Retrospective Claims Analysis

  POSTER ABSTRACT

• Impact of Adhesion on Patient Satisfaction, Medication Switching and Discontinuation With Lidocaine Topical Patches Based on FDA Adverse Event Reporting and Patient Surveys

  POSTER ABSTRACT

• Review of Multimodal Therapies for the Treatment of Neuropathic Pain: Clinical Implications

  POSTER ABSTRACT